just playing around by applying IMMU buyout scenario to CKPT

When Immunomedics (IMMU) received FDA approval for Trodelvy (sacituzumab govitecan) on April 22, 2020, the average analyst price target for the company’s stock stood at $32 per share.

At the time of Trodelvy’s FDA approval on April 22, 2020, revenue expectations were optimistic given its potential in oncology. Analysts projected annual sales to reach $1 billion to $3 billion in peak revenue over time, depending on its expansion into additional cancer indications and global markets.

The buyout price for Immunomedics (IMMU) by Gilead Sciences was $88 per share in cash.

$22 -> $88 about 4times, Mkt Cap from $5B to $20B with about $2B sales expected drug at the moment. far beyond Analysts target price, 2.7times.

CKPT

Mkt Cap $200M now with over $1B sales expected drug with further potentials.

CKPT is 25 times undervalued than IMMU when FDA get approved.

simply giving 2times multiple on average Analysts target price would be $24.

additionally if we can give just 2times multiple on undervaluation would be $48.

lets go CKPT! show me the money